Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

New nuclear reactor for medical isotope production comes online in east China's Zhejiang (Voice_over) One of China's nuclear ...

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Small-Cell Lung Cancer.

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase I for Neuroendocrine Cancer. According to GlobalData, Phase I drugs for ...

( NucNet contributed to this report) India’s state owned enterprise Nuclear Power Corporation of India Limited (NPCIL) announced this week it is inviting proposals to build a fleet of 40-50 220 MW ...

What new medicines are poised to take the leap from breakthrough to approval in 2025? Here’s what to expect this year.

China National Nuclear Corporation’s (CNNC) first-ever commercial reactor for the production of isotopes has officially ...

Scientists at Russia’s Research Institute of Nuclear Materials (INM JSC) have developed a technology for the production of ...

Rare earth elements are essential for modern military and civilian technology. They’re found most often in hard-to-reach ...

The expansion of the Isotope Production System (IPS) and cobalt-60 production capabilities were also highlights in 2024, ...

This year, Novartis’ deal-making in the area paid off when it received US FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for previously-treated patients with PSMA-positive ...